An Alzheimer's blood biomarker test is a blood test that looks for proteins linked to changes in the brain caused by Alzheimer's disease. It measures substances such as amyloid-beta and tau that can help doctors determine whether Alzheimer's-related changes may be present. The test is a less invasive way to support an Alzheimer's diagnosis, but its results must be considered alongside memory symptoms and other medical evaluations.
How Does the Alzheimer's Blood Biomarker Test Work?
Alzheimer's disease is associated with changes in certain proteins in the brain. Two important proteins are amyloid-beta and tau. Amyloid-beta can build up into plaques between nerve cells, while abnormal tau can form tangles inside nerve cells. These changes are important biological features of Alzheimer's disease.
Small amounts of these proteins, or related forms of them, can be measured in the bloodstream. Blood biomarker tests use laboratory technology to detect these substances and identify patterns associated with Alzheimer's-related brain changes.
According to Mayo Clinic, a blood biomarker called phosphorylated tau 217, or p-tau217, can help identify Alzheimer's-related changes in people experiencing problems with memory or thinking.
The test does not directly examine brain tissue. Instead, it provides information about biological markers that may reflect what is happening in the brain.
Which Blood Biomarkers Are Used to Detect Alzheimer's Disease?
Different Alzheimer's blood tests measure different proteins or combinations of proteins. The most important markers currently used or studied include amyloid-beta and several forms of phosphorylated tau.
Amyloid-Beta 42 and Amyloid-Beta 40
Amyloid-beta is a protein fragment involved in the formation of amyloid plaques, a characteristic feature of Alzheimer's disease.
Some blood tests measure two forms of this protein, called amyloid-beta 42 (Aβ42) and amyloid-beta 40 (Aβ40). Laboratories may calculate the ratio between these forms rather than relying on either measurement alone.
The Aβ42/Aβ40 ratio can help estimate whether amyloid plaques are likely to be present in the brain. However, the usefulness of this measurement depends on the particular test and its accuracy.
Phosphorylated Tau 217 (p-tau217)
Phosphorylated tau 217 is a form of the tau protein that has attracted considerable attention in Alzheimer's blood testing.
Higher blood levels of p-tau217 are associated with Alzheimer's-related brain changes. In people already experiencing cognitive difficulties, this marker may help distinguish Alzheimer's-related changes from other possible explanations for those symptoms.
Other Phosphorylated Tau Markers
Researchers and laboratories also examine other forms of phosphorylated tau, including p-tau181 and p-tau231. These markers may provide information about Alzheimer's-related pathology, although their diagnostic performance is not identical.
The Alzheimer's Association clinical practice guideline, published through the National Library of Medicine, evaluates several amyloid-beta and phosphorylated tau measurements and emphasizes that accuracy varies considerably among available blood biomarker tests.
Who Should Get an Alzheimer's Blood Biomarker Test?
Blood biomarker testing is primarily intended to help evaluate people who already have signs of cognitive impairment and are being assessed for possible Alzheimer's disease.
A healthcare professional may consider the test when someone has ongoing changes in memory, reasoning, or other thinking abilities that warrant investigation.
Examples of difficulties that may lead to a medical assessment include:
- Increasing difficulty remembering recent conversations or information.
- Repeatedly asking the same questions because recent information is forgotten.
- Having trouble planning, organizing, or completing familiar activities.
- Experiencing changes in language, judgment, or problem-solving abilities.
- Having cognitive difficulties that interfere with everyday responsibilities.
These experiences can have several possible causes. A clinician first considers the person's history, symptoms, examination, and cognitive testing before deciding whether an Alzheimer's biomarker test would be useful.
Can Healthy Adults Get Tested Before Symptoms Appear?
Blood biomarker testing is not currently recommended as routine Alzheimer's screening for people who have no cognitive symptoms.
Even when someone has a family history of Alzheimer's disease, a blood test is not generally recommended solely to estimate future disease risk in an otherwise symptom-free person.
Blood biomarkers can reveal biological changes, but identifying those changes does not necessarily establish whether or when someone will develop noticeable cognitive symptoms.
Is There an Age Requirement?
Age requirements depend on the specific test. In May 2025, the U.S. Food and Drug Administration cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test for adults aged 55 and older who have signs and symptoms suggestive of Alzheimer's disease.
The age limit for this particular test should not be assumed to apply to every blood biomarker test or research application.
How Is the Alzheimer's Blood Test Performed?
The procedure is similar to a standard blood test and does not require a brain scan or spinal fluid collection.
The usual process involves:
- Clinical assessment: A healthcare professional reviews the patient's symptoms and determines whether biomarker testing is appropriate.
- Blood collection: A healthcare worker takes a blood sample from a vein, usually in the arm.
- Laboratory analysis: The sample is examined for the proteins or protein ratios measured by the selected test.
- Result interpretation: The clinician reviews the findings alongside the patient's cognitive assessment and other medical information.
- Follow-up: Additional testing may be recommended when results are uncertain or further confirmation is needed.
The blood draw itself generally takes only a few minutes. The time needed to receive results depends on the laboratory and the specific assay.
Preparation instructions also vary. Patients should follow the laboratory's directions rather than assuming that fasting or medication changes are necessary.
How Accurate Is the Alzheimer's Blood Biomarker Test?
Some newer Alzheimer's blood biomarker tests have demonstrated high accuracy in identifying Alzheimer's-related pathology among people undergoing evaluation for cognitive symptoms. However, accuracy depends on the test being used, the population being evaluated, and how results are interpreted.
The National Institutes of Health reported on a 2024 study in which a blood biomarker test predicted Alzheimer's disease with approximately 88% to 92% accuracy among patients evaluated in primary care and specialty memory clinics.
These findings are encouraging, but they do not mean every available blood test achieves the same results.
What Does Test Accuracy Mean?
Two important measures are sensitivity and specificity.
- Sensitivity: How often a test correctly identifies people who have the Alzheimer's-related brain changes being measured.
- Specificity: How often it correctly identifies people who do not have those changes.
A highly sensitive test may be useful for deciding who needs further investigation. A test with both high sensitivity and high specificity may provide stronger evidence about the presence or absence of Alzheimer's-related pathology.
The Alzheimer's Association's 2025 specialty-care guideline supports using tests with at least 90% sensitivity and 75% specificity as triage tools. Tests achieving at least 90% sensitivity and 90% specificity may be used in place of certain confirmatory biomarker investigations in appropriate specialist settings.
These performance standards apply to the intended clinical setting. They do not mean that a result is always correct or that biomarker testing replaces the broader clinical evaluation.
What Do Positive, Negative, or Uncertain Results Mean?
The meaning of a blood biomarker result depends on the particular assay, its reference thresholds, and the person's clinical situation.
Positive Result
A positive result suggests that Alzheimer's-related brain changes, such as amyloid plaques, may be present.
For a person experiencing cognitive impairment, this finding can strengthen the possibility that Alzheimer's pathology is contributing to their symptoms.
However, a positive biomarker result does not, by itself, explain the full cause of every cognitive difficulty or determine how advanced the person's symptoms are.
Negative Result
A negative result suggests that the specific Alzheimer's-related changes being measured are less likely to be present.
This may help clinicians consider other explanations for memory or thinking difficulties. Because false-negative results can occur, the result must still be interpreted in the clinical context.
Indeterminate Result
Some tests return an indeterminate result when the measured biomarker levels fall into a range that cannot be classified confidently as positive or negative.
In this situation, a healthcare professional may recommend additional evaluation, such as an amyloid PET scan or cerebrospinal fluid testing, if the result would meaningfully affect diagnosis or treatment decisions.
Is the Alzheimer's Blood Test FDA-Cleared?
Yes. The first blood-based diagnostic device cleared by the U.S. FDA to aid in diagnosing Alzheimer's disease was the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, cleared on May 16, 2025.
The test measures p-tau217 and amyloid-beta 1-42 in blood plasma and calculates a ratio associated with amyloid plaques in the brain.
According to the U.S. Food and Drug Administration, a clinical study involving 499 samples from cognitively impaired adults found that 91.7% of people with positive test results had evidence of amyloid plaques on comparison testing. Among those with negative results, 97.3% had negative comparison findings.
These figures describe the results of that particular clinical study, not the expected accuracy of all Alzheimer's blood tests.
FDA clearance also does not make the Lumipulse test a stand-alone diagnostic tool. It is intended to support clinical assessment in the population for which it was evaluated.
How Does a Blood Test Compare With a PET Scan or Spinal Fluid Test?
Doctors have traditionally used specialized brain imaging and cerebrospinal fluid testing to investigate biological signs of Alzheimer's disease.
Amyloid PET Scan
An amyloid positron emission tomography (PET) scan uses a specialized imaging tracer to help identify amyloid plaques in the brain.
It provides information about brain amyloid pathology but requires specialized equipment and imaging facilities.
Cerebrospinal Fluid Test
Cerebrospinal fluid testing measures Alzheimer's-related proteins in the fluid surrounding the brain and spinal cord.
Collecting the sample requires a lumbar puncture, also called a spinal tap. This involves inserting a needle into the lower back to obtain spinal fluid.
Blood Biomarker Test
A blood test requires only a standard blood sample, making the collection process simpler and less invasive than a lumbar puncture.
One important advantage is that appropriately validated blood tests may reduce the number of people who need PET imaging or spinal fluid testing. However, these investigations remain useful in selected cases, especially when findings are unclear or do not match the clinical picture.
Why Might a Doctor Recommend This Test?
The main purpose of an Alzheimer's blood biomarker test is to provide more specific evidence about whether Alzheimer's pathology may be contributing to cognitive symptoms.
That information can be useful for several reasons.
Clarifying the Cause of Cognitive Problems
Memory and thinking problems can arise from different medical conditions. An Alzheimer's biomarker test may help clinicians distinguish Alzheimer's-related pathology from other possible causes during a complete diagnostic assessment.
Deciding Whether More Testing Is Necessary
A blood biomarker result may help determine whether additional investigations, including amyloid PET imaging or cerebrospinal fluid analysis, are warranted.
Supporting Treatment Decisions
Some Alzheimer's treatments are intended for selected patients with early symptomatic disease and require confirmation of amyloid pathology before treatment begins.
An appropriately validated blood biomarker test may help with the diagnostic assessment needed to consider such treatment. Eligibility still depends on other clinical factors, and additional testing may be necessary.
The Alzheimer's Association emphasizes that blood biomarker tests should be used after comprehensive clinical evaluation and interpreted by healthcare professionals within the patient's diagnostic context.
What Are the Limitations of Alzheimer's Blood Testing?
Although blood biomarker testing represents an important development in Alzheimer's assessment, several limitations remain.
- Results are not always definitive: False-positive, false-negative, and indeterminate results can occur.
- Tests differ in performance: Not all commercially available assays have the accuracy needed for the same clinical uses.
- Biomarkers do not fully describe symptoms: A blood result cannot independently measure the extent of someone's memory difficulties or everyday functioning.
- Testing is not intended for general screening: Clinical recommendations focus on selected patients with cognitive impairment rather than symptom-free adults.
- Availability varies: Access depends on the country, healthcare system, laboratory, and specific test.
For these reasons, the result is most useful when interpreted by a clinician experienced in assessing cognitive disorders.
What Happens After an Alzheimer's Blood Biomarker Test?
After the laboratory provides the results, the healthcare professional considers whether the findings match the patient's symptoms, medical history, and cognitive assessment.
Depending on the findings, the next step may involve discussing the likely cause of the cognitive difficulties, arranging additional tests, or considering appropriate care and treatment options.
Other tests may also be needed to investigate conditions that can contribute to memory or thinking problems, such as thyroid disorders or vitamin B12 deficiency.
Patients and families can ask the clinician what the specific biomarker result means, whether further confirmation is needed, and how it may influence treatment decisions.
The Bottom Line
Alzheimer's blood biomarker tests offer a less invasive way to look for biological signs associated with Alzheimer's disease. By measuring proteins such as amyloid-beta and phosphorylated tau, these tests can provide useful information during the evaluation of memory and thinking difficulties.
Some validated tests can help reduce reliance on PET scans or spinal fluid testing, but their usefulness depends on accuracy and the clinical situation. A healthcare professional should interpret the findings as part of a complete assessment rather than relying on the blood result alone.